{"id":32831,"date":"2025-11-05T10:07:08","date_gmt":"2025-11-05T15:07:08","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=32831"},"modified":"2026-05-06T10:44:34","modified_gmt":"2026-05-06T14:44:34","slug":"what-is-drug-product-hopping-a-deep-dive-into-drug-product-hopping-and-its-impact-on-the-pharmaceutical-industry","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/what-is-drug-product-hopping-a-deep-dive-into-drug-product-hopping-and-its-impact-on-the-pharmaceutical-industry\/","title":{"rendered":"Drug Product Hopping: The Complete IP and Antitrust Playbook for Pharma Teams"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

A brand-name drug loses 90% of its market share within 12 months of generic entry. That single data point explains almost everything about why pharmaceutical lifecycle management exists, why product hopping has become one of the industry’s most contested strategies, and why the FTC has spent the better part of two decades trying to contain it. This guide covers the full mechanics, the IP architecture, the case law, and the competitive intelligence infrastructure you need to operate on either side of this market.<\/p>\n\n\n\n

\n\n\n\n

What Drug Product Hopping Actually Is<\/strong><\/h2>\n\n\n\n

Drug product hopping is a lifecycle management strategy in which a brand manufacturer transitions physician prescribing and patient use from an older, patent-expiring formulation to a newer, patent-protected version, timed specifically to disrupt generic substitution at the moment of generic entry.<\/p>\n\n\n\n

The word ‘hop’ is precise. The manufacturer jumps the franchise over the patent cliff, landing on a reformulated product with a fresh exclusivity runway. The generic manufacturer, which spent three to five years reverse-engineering the original product and prosecuting its ANDA, finds the market it targeted has been vacated by design.<\/p>\n\n\n\n

The distinction between product hopping and ordinary lifecycle management is intent and timing. Every pharmaceutical company extends product lines. The hallmark of a product hop is that the switch to the new formulation is engineered to prevent therapeutic equivalence-based automatic substitution under state pharmacy law, not merely to offer patients a new option.<\/p>\n\n\n\n

How Automatic Substitution Law Creates the Incentive<\/strong><\/h3>\n\n\n\n

State pharmacy substitution laws, which in most U.S. states require or permit pharmacists to dispense an AB-rated generic in place of a branded drug without a new prescription, are the economic engine of the generic market. They are also the mechanism that product hopping is designed to defeat.<\/p>\n\n\n\n

For a pharmacist to substitute a generic, the FDA’s Orange Book must list that generic as therapeutically equivalent (AB-rated) to the product on the prescription. If the brand has shifted the market to a new formulation, the prescription now references a product for which no generic equivalent exists yet. Automatic substitution is blocked at the pharmacy level without any court intervention.<\/p>\n\n\n\n

This is the core mechanics: break the chain of therapeutic equivalence, and you break the substitution pathway. The generic’s path to market narrows from an automatic swap to a physician re-education campaign, which is orders of magnitude harder.<\/p>\n\n\n\n

\n\n\n\n

The IP Architecture of a Product Hop<\/strong><\/h2>\n\n\n\n

How Reformulation Patents Get Built and Stacked<\/strong><\/h3>\n\n\n\n

A successful product hop is not a single patent play. It is an IP stack assembled over several years, often beginning at the same time as the NDA for the original product is filed. Understanding the specific layers of this stack is essential for generic companies assessing litigation strategy and for IP counsel modeling franchise longevity.<\/p>\n\n\n\n

The primary patent on the active pharmaceutical ingredient (API) is typically the oldest and most vulnerable to challenge. It is also the one the generic manufacturer targets first with a Paragraph IV certification. Brand companies know this. The lifecycle management strategy starts with layering secondary patents on top of the API before or shortly after launch.<\/p>\n\n\n\n

For a typical oral small-molecule drug, the secondary patent stack might include a formulation patent covering the specific excipient combination in the tablet, a polymorph patent covering a particular crystalline form of the API, a method-of-use patent for the primary indication, and a dosage-regimen patent covering the specific titration schedule. Each of these can trigger a 30-month stay upon a Paragraph IV filing, and each represents an additional litigation hurdle for the generic company.<\/p>\n\n\n\n

The product hop introduces a new layer. By developing an extended-release formulation, a fixed-dose combination, or a new delivery mechanism, the brand files patents covering the new formulation and secures three years of Hatch-Waxman exclusivity for the new product by conducting new clinical trials under 21 U.S.C. 355(c)(3)(E)(iii). That three-year exclusivity period is separate from patent protection. It prevents approval of any ANDA or 505(b)(2) NDA that references the new product as the reference listed drug (RLD), creating a window during which the generic company cannot even get an approved product to market, regardless of how strong the litigation case looks.<\/p>\n\n\n\n

The Reference Listed Drug Problem<\/strong><\/h3>\n\n\n\n

The RLD designation is the linchpin of ANDA strategy. When a brand company hops its product and the FDA lists the new formulation as the RLD (or when the old product is withdrawn and delisted), the generic that was approved or pending against the old product loses its substitutability anchor. The generic’s approved application does not automatically transfer to the new product. It must file a new ANDA or 505(b)(2) against the new RLD and start the clock again.<\/p>\n\n\n\n

If the old product is withdrawn from the market before the generic launches, the generic company faces a second problem: the FDA may suspend or withdraw the ANDA approval because the RLD is no longer commercially marketed. Under 21 C.F.R. 314.161, the FDA can withdraw ANDA approval if the brand withdraws the listed drug for reasons other than safety or effectiveness. This regulatory mechanism is one of the more powerful tools available in a hard-switch product hop.<\/p>\n\n\n\n

IP Valuation: What a Hopped Franchise Is Actually Worth<\/strong><\/h3>\n\n\n\n

For portfolio managers and BD teams assessing a brand franchise, the IP value of a hopped product line requires a more granular model than a simple patent expiry date analysis.<\/p>\n\n\n\n

The key variables are the strength and remaining life of the lead formulation patent on the new product, the outcome probability on any pending Paragraph IV litigation challenging that patent, the three-year Hatch-Waxman exclusivity expiry date for the new formulation, the market penetration rate of the new product relative to the original at the time of any generic entry into the old product’s market, and the litigation risk from antitrust challenges to the switch itself.<\/p>\n\n\n\n

A franchise where 85% of prescriptions have already transitioned to the new formulation before the old product’s generic entry is structurally more defensible than one where the switch is 40% complete. The first scenario means the generic entering the market for the old product captures only 15% of the original revenue base, and only after winning on the merits.<\/p>\n\n\n\n

Analysts should model three scenarios: the base case (successful hop, new formulation’s patents hold through their listed expiry), the litigation-adverse case (Paragraph IV challenge succeeds, generic enters the new product’s market early), and the antitrust-adverse case (court enjoins the hard switch, restoring the old product and enabling generic substitution).<\/p>\n\n\n\n

Key Takeaways: IP Architecture<\/strong><\/p>\n\n\n\n

The three-year Hatch-Waxman new clinical investigation exclusivity on a reformulated product is often more valuable than the formulation patent itself, because it blocks ANDA approval regardless of litigation outcome. Secondary patent stacks assembled before the original product’s API patent expires are standard practice; a generic company that has not mapped the full Orange Book listing for its target product before filing its ANDA is operating blind. RLD delisting upon a voluntary withdrawal is a material litigation risk for any pending ANDA.<\/p>\n\n\n\n

\n\n\n\n

The Four Core Product Hopping Tactics<\/strong><\/h2>\n\n\n\n

Immediate-Release to Extended-Release Conversion<\/strong><\/h3>\n\n\n\n

This is the canonical product hop. The original API, which has established safety and efficacy, gets reformulated into an extended-release matrix or membrane-controlled delivery system. The clinical justification is adherence: patients taking one pill per day instead of two are more likely to maintain therapy, particularly in chronic disease management where asymptomatic patients have low motivation for strict dosing.<\/p>\n\n\n\n

The pharmacokinetic profile changes enough that the FDA treats the ER formulation as a distinct product requiring its own NDA and generating its own Orange Book listing. The generic manufacturer that filed an ANDA against the IR product cannot substitute the ER brand, regardless of bioequivalence.<\/p>\n\n\n\n

The Namenda case (discussed in depth below) is the definitive example. Forest Laboratories’ Namenda IR (memantine hydrochloride) was approved in 2003 for moderate-to-severe Alzheimer’s disease, requiring twice-daily dosing. Namenda XR, a once-daily extended-release capsule, launched in 2010 as the franchise’s IR patent position began to erode. By 2014, Forest began the hard switch, announcing plans to discontinue IR. The subsequent litigation established that this combination of actions could constitute illegal monopoly maintenance.<\/p>\n\n\n\n

From an IP valuation standpoint, Namenda XR carried a patent on its extended-release formulation (U.S. Patent No. 8,039,009) expiring in 2025, plus pediatric exclusivity, giving the XR franchise roughly a decade of additional protection after IR generics would have entered.<\/p>\n\n\n\n

Dosage Form Switching: Tablet to Capsule, Capsule to Film<\/strong><\/h3>\n\n\n\n

Warner Chilcott’s management of the Doryx (doxycycline hyclate) franchise is the most studied example of dosage form switching as a product hop. Doryx originally came as delayed-release tablets in 75mg and 100mg strengths. As each strength approached generic entry, the company introduced a new tablet strength (150mg) and then, more aggressively, converted the entire product line from tablets to capsules.<\/p>\n\n\n\n

The legal significance of tablet-to-capsule switches lies in state pharmacy law. Many states restrict automatic substitution to products of identical dosage form. A generic delayed-release doxycycline tablet is not substitutable for a branded delayed-release doxycycline capsule in those states, even at the same dose of the same active ingredient. The brand has separated the product from its generic by a regulatory formality.<\/p>\n\n\n\n

The Third Circuit’s 2010 analysis of the Doryx situation established that a series of sequential product switches, each timed to preempt generic entry, can collectively constitute anti-competitive conduct even if each individual switch appears minor in isolation. The court evaluated the pattern, not just the individual acts.<\/p>\n\n\n\n

The Suboxone (buprenorphine\/naloxone) case extends this logic to a more complex setting. Reckitt Benckiser’s original Suboxone came as a sublingual tablet. The reformulated product was a sublingual film that dissolved faster and came in individual child-resistant foil pouches rather than a multi-dose bottle. Reckitt’s stated rationale was pediatric safety, citing the risk of accidental pediatric exposure from multi-dose tablet bottles. The FTC’s complaint alleged that the safety rationale was pretextual and that Reckitt had internally documented the competitive motivation.<\/p>\n\n\n\n

The $1.4 billion settlement Reckitt paid in 2019 to resolve DOJ and state attorney general claims remains the largest single resolution in a pharmaceutical product hop case. It also demonstrated that even where a genuine clinical benefit exists for the new formulation, the underlying competitive intent and the tactics used to execute the switch carry independent legal risk.<\/p>\n\n\n\n

Fixed-Dose Combinations<\/strong><\/h3>\n\n\n\n

Fixed-dose combination (FDC) products combine the anchor molecule with one or more additional active ingredients, typically agents already generic or near-generic themselves. The resulting combination product has its own NDA, its own Orange Book listing, and its own patent and exclusivity protection.<\/p>\n\n\n\n

The strategic logic is straightforward: a patient on both a branded antihypertensive and a generic beta-blocker can be transitioned to a single branded combination pill. The brand captures additional daily revenue from the previously generic component, and the combination product is not substitutable with either individual component.<\/p>\n\n\n\n

AstraZeneca’s management of the esomeprazole franchise provides a widely cited example. After omeprazole (the racemate) lost exclusivity, AstraZeneca launched esomeprazole (the S-enantiomer) as Nexium. As Nexium itself approached patent expiry, combination formulations entered the pipeline. Vimovo, a combination of esomeprazole and naproxen aimed at patients requiring NSAID therapy with gastroprotection, represented exactly this kind of franchise extension. The combination product’s development and marketing costs were modest compared to a first-in-class NDA; the commercial benefit was a new exclusivity window.<\/p>\n\n\n\n

From an antitrust perspective, FDC-based product hops are generally less vulnerable than hard-switch IR-to-ER conversions, because the combination product genuinely adds something the individual components cannot replicate in a single administration. Courts and regulators have been more willing to accept the patient benefit rationale here. The risk increases when the brand discontinues the individual components and forces patients onto the combination, at which point the coercive element returns.<\/p>\n\n\n\n

Enantiomer Switching and Molecular Reformulation<\/strong><\/h3>\n\n\n\n

Chiral switching involves developing a single enantiomer of a racemic API as a new chemical entity. The new enantiomer may have a slightly improved pharmacokinetic profile, a cleaner side effect burden, or simply the same therapeutic profile in a smaller dose. Regardless, the FDA may treat it as a new molecular entity (NME) eligible for five-year Hatch-Waxman exclusivity, the longest available under the statute.<\/p>\n\n\n\n

The omeprazole-to-esomeprazole switch is the prototype. Omeprazole (Prilosec) was marketed as the racemate; esomeprazole (Nexium) is the S-enantiomer. AstraZeneca launched Nexium in 2001, one year before major omeprazole patents expired, and aggressively transitioned prescribers. The clinical trials submitted to the FDA showed marginally superior healing rates at higher doses, but the magnitude of clinical difference was contested. Generic omeprazole entered at a fraction of Nexium’s price. AstraZeneca’s ability to sustain Nexium’s market share despite available generic omeprazole reflected the success of physician detailing and formulary positioning rather than clinical differentiation, according to analyses by consumer and generic industry groups.<\/p>\n\n\n\n

Celecoxib’s position in the COX-2 inhibitor market after the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra) is a different but instructive case of asset repositioning. With competitors withdrawn, Pfizer’s Celebrex gained an extended de facto monopoly within the surviving COX-2 class. The lifecycle management question became: how to transition from Celebrex before its LOE to a next-generation formulation that could sustain the franchise.<\/p>\n\n\n\n

Key Takeaways: Tactics<\/strong><\/p>\n\n\n\n

No single tactic is more legally vulnerable than the hard switch accompanying an IR-to-ER conversion. FDC-based hops are more defensible provided the original components remain available. Chiral switching can produce NME status and five-year exclusivity, making it one of the most IP-efficient lifecycle management tools available. Sequential dosage form switches, evaluated as a pattern, can constitute anti-competitive conduct even when each individual switch is minor.<\/p>\n\n\n\n

\n\n\n\n

The Soft Switch and the Hard Switch: A Legal Risk Framework<\/strong><\/h2>\n\n\n\n

Defining the Boundary<\/strong><\/h3>\n\n\n\n

The distinction between a soft switch and a hard switch is the single most consequential variable in a product hop’s legal risk profile. The Second Circuit’s 2015 Namenda decision made this explicit: the relevant question is not whether the brand introduced a new and better product, but whether it took additional coercive steps to eliminate the old product and with it, the competitive market for generic entry.<\/p>\n\n\n\n

A soft switch preserves the old product on the market and relies on physician detailing, direct-to-consumer advertising, formulary negotiations, and patient assistance programs to shift prescribing to the new formulation. The generic company that launches a product for the old formulation still has a market. It may be a diminished one, but the substitution mechanism remains intact.<\/p>\n\n\n\n

A hard switch removes the old product from the market before or concurrent with generic entry. It is not a marketing decision. It is a structural market intervention using monopoly power over the existing product to foreclose competition for the product’s active ingredient.<\/p>\n\n\n\n

The Namenda Decision: Legal Standard in Detail<\/strong><\/h3>\n\n\n\n

The Second Circuit’s opinion in New York ex rel. Schneiderman v. Actavis plc, 787 F.3d 638 (2d Cir. 2015), is the controlling authority on hard-switch product hopping in the dominant circuit for pharmaceutical antitrust litigation. The court framed the central issue precisely: ‘The question is not whether Defendants acted with a legitimate business purpose, but whether Defendants’ conduct is the kind that could harm competition.’<\/p>\n\n\n\n

The court found that withdrawing Namenda IR would not benefit competition or consumers. The new product (XR) would still be available. The coercive element was the removal of the old product. That act, combined with the market transition campaign, constituted attempted monopolization under Section 2 of the Sherman Act.<\/p>\n\n\n\n

The preliminary injunction the New York Attorney General obtained required Forest\/Actavis to keep Namenda IR on the market, which in effect preserved the market into which generic memantine IR could enter. Generic memantine IR launched in 2015.<\/p>\n\n\n\n

The financial stakes of the litigation were substantial. The NYAG’s complaint alleged that the hard switch would cost patients and insurers approximately $300 million per year in avoided generic savings. Forest’s market capitalization moved meaningfully on the court’s ruling.<\/p>\n\n\n\n

The Suboxone Case: Intent Evidence and Settlement Dynamics<\/strong><\/h3>\n\n\n\n

The Suboxone litigation added a dimension the Namenda case did not fully address: the relevance of internal corporate communications documenting anti-competitive intent. Reckitt’s internal documents, obtained during discovery and cited in the DOJ complaint, included material suggesting that the film transition was primarily motivated by competitive defense rather than the stated pediatric safety rationale.<\/p>\n\n\n\n

The evidentiary significance of this is considerable for litigation strategy. A brand company executing a product hop should treat its internal R&D, marketing, and strategy communications as potential exhibits in future antitrust litigation. The business case for a formulation switch should document clinical and patient benefit rationale contemporaneously, not as post-hoc litigation support.<\/p>\n\n\n\n

The $1.4 billion Reckitt settlement included both criminal and civil components, with Reckitt’s subsidiary Indivior separately prosecuted for marketing conduct. The scale of the settlement reflects both the duration of the alleged conduct and the volume of government healthcare spending on Suboxone.<\/p>\n\n\n\n

Investment Strategy: Antitrust Litigation Risk<\/strong><\/p>\n\n\n\n

Institutional investors holding brand pharma positions should price in antitrust litigation risk when a hard switch is announced. The Namenda decision demonstrated that courts will grant preliminary injunctions preserving the old product’s market. The asset value of the hopped product remains intact; the litigation risk is to the transition timeline and the costs of preserving the old product longer than planned. The larger risk is a scenario where an unfavorable antitrust ruling requires divestiture or damage payments, as in the Reckitt case. Firms running DCF models on branded pharmaceutical assets should include a probability-weighted antitrust haircut when the product is in a hard-switch transition.<\/p>\n\n\n\n

\n\n\n\n

How the Hatch-Waxman Framework Enables and Constrains the Hop<\/strong><\/h2>\n\n\n\n

The 1984 Compromise and Its Structural Tensions<\/strong><\/h3>\n\n\n\n

The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) built the architecture of the U.S. drug market as it now exists. Its core bargain was straightforward: brand companies get patent term extensions to compensate for regulatory review time, and generic companies get an abbreviated approval pathway (the ANDA) that requires only bioequivalence data, not duplicative safety and efficacy trials.<\/p>\n\n\n\n

The Act presupposes a relatively stable reference product. The ANDA process is designed around the idea that a generic manufacturer identifies a listed drug in the Orange Book, proves its product is bioequivalent to that listed drug, certifies against any listed patents, and enters the market. Product hopping exploits the tension in this design: when the brand changes the listed drug, the entire ANDA framework is temporarily unmoored.<\/p>\n\n\n\n

Exclusivity Stacking: The Mechanics<\/strong><\/h3>\n\n\n\n

The Hatch-Waxman Act provides multiple exclusivity categories that can accumulate on a single franchise:<\/p>\n\n\n\n

Five-year new chemical entity (NCE) exclusivity applies when the active moiety has not previously been approved. The enantiomer switch strategy often seeks NME designation to access this exclusivity period, which blocks ANDA and 505(b)(2) submissions for the first four years.<\/p>\n\n\n\n

Three-year new clinical investigation exclusivity applies when the NDA for a new formulation, new indication, or new combination includes clinical trials that were essential to the approval. This blocks ANDA approval (not submission) for three years from the new product’s approval date. Generic companies can file ANDAs during the three-year period, but FDA cannot approve them until the exclusivity expires.<\/p>\n\n\n\n

Pediatric exclusivity (six months) attaches to the existing exclusivity or patent term when the brand conducts pediatric studies requested by the FDA under the Best Pharmaceuticals for Children Act (BPCA). It applies to all formulations of the active moiety, including the new hopped formulation.<\/p>\n\n\n\n

Orphan drug exclusivity (seven years) applies when the FDA grants orphan designation for a rare disease indication. Brand companies have sought orphan designations for subpopulations or rare forms of diseases treated by the core product, then used the resulting exclusivity to protect formulations serving the broader market.<\/p>\n\n\n\n

The stack in practice: a brand that converts from IR to ER near the end of the IR’s patent life, qualifies the ER for three-year clinical investigation exclusivity, obtains pediatric exclusivity on the ER, and lists several formulation patents on the ER creates a wall of protection lasting potentially six or more years beyond the original API patent expiry.<\/p>\n\n\n\n

The 30-Month Stay Mechanism<\/strong><\/h3>\n\n\n\n

When a generic company files an ANDA and certifies under Paragraph IV that a listed patent is invalid or not infringed, the brand can sue within 45 days to trigger an automatic 30-month stay on FDA approval. The 30-month stay is the generic industry’s most significant delay mechanism.<\/p>\n\n\n\n

In the context of a product hop, a brand that has stacked multiple Paragraph IV-eligible patents on the new formulation can trigger successive 30-month stays if each patent is listed in the Orange Book before the ANDA is filed. In practice, FTC scrutiny and judicial efficiency rules limit the most egregious stacking, but even two successive stays can delay generic entry by five or more years beyond the first patent expiry date.<\/p>\n\n\n\n

Key Takeaways: Hatch-Waxman<\/strong><\/p>\n\n\n\n

Three-year new clinical investigation exclusivity is the most consistently underestimated IP tool in lifecycle management strategy. It blocks ANDA approval, not just submission, meaning an ANDA can be pending for years with no legal ability for the FDA to approve it. Pediatric exclusivity attaches to all approved formulations of the active moiety, making it one of the most cost-efficient extensions available. Generic companies assessing a product hop target should model all exclusivity expiry dates, not just patent expiry dates.<\/p>\n\n\n\n

\n\n\n\n

Biologics: Product Hopping in a More Complex Arena<\/strong><\/h2>\n\n\n\n

Why Biologic Franchise Defense Is Structurally Different<\/strong><\/h3>\n\n\n\n

The dynamics of product hopping in biologics differ from small-molecule drugs in several important respects. The underlying regulatory framework (the Biologics Price Competition and Innovation Act of 2009, or BPCIA) has different exclusivity terms (12 years for reference product exclusivity plus four years before any biosimilar can be submitted), a different interchangeability standard, and a product complexity that makes simple formulation switches more scientifically significant.<\/p>\n\n\n\n

The biosimilar approval pathway requires demonstrating no clinically meaningful differences from the reference biologic in terms of safety, purity, and potency. Interchangeability, the higher standard that permits automatic pharmacy substitution, requires additional data showing that switching between the reference product and the biosimilar does not increase safety or efficacy risks compared to using the reference product alone.<\/p>\n\n\n\n

This structural complexity gives biologic brand holders more inherent franchise protection than small-molecule brands. A reference biologic faces a higher substitution threshold than a small-molecule drug. But it also means that product hopping in biologics takes different forms.<\/p>\n\n\n\n

PEGylation and Half-Life Extension as a Lifecycle Tool<\/strong><\/h3>\n\n\n\n

The most common biologic product hop involves modifying the molecule to extend its circulating half-life, allowing for less frequent dosing. PEGylation, the attachment of polyethylene glycol chains to the biologic molecule, is the most established technique. The resulting ‘pegylated’ product is pharmacokinetically distinct from the original, may have improved tolerability, and is a new molecular entity for regulatory purposes.<\/p>\n\n\n\n

Roche’s pegfilgrastim (Neulasta) versus filgrastim (Neupogen) is the prototypical case. Both stimulate neutrophil production in patients receiving chemotherapy; filgrastim requires daily injections during the risk window while pegfilgrastim is dosed once per chemotherapy cycle. The once-per-cycle dosing represents a genuine clinical convenience benefit that generated years of additional market exclusivity for Roche beyond filgrastim’s protection.<\/p>\n\n\n\n

The relevant IP question for biosimilar developers is whether the pegylated product is biosimilar to the original or constitutes a separate reference product requiring its own biosimilar NDA. The FDA has generally treated PEGylated biologics as distinct from their unmodified parents, meaning a biosimilar to pegfilgrastim must be developed and approved separately from a biosimilar to filgrastim.<\/p>\n\n\n\n

Amgen’s Enbrel (etanercept) franchise and the broader TNF-inhibitor class illustrate multi-product lifecycle management in biologics. As the reference product exclusivity on the core etanercept molecule approached expiry, Amgen’s investments in subcutaneous formulation optimization, auto-injector device improvements, and patient support programs created a stickiness that pure IP protection could not deliver. This is lifecycle management through service and convenience rather than molecular modification, and it operates largely outside the antitrust framework that governs product hops.<\/p>\n\n\n\n

The ‘Bio-Better’ Strategy<\/strong><\/h3>\n\n\n\n

A bio-better is a next-generation biologic designed to improve on the original molecule’s clinical profile, not merely match it. Common improvements include longer half-life (through PEGylation or Fc fusion), improved dosing interval, reduced immunogenicity, or enhanced potency. Bio-betters are filed as new biologics, not as biosimilars, and they qualify for full 12-year reference product exclusivity.<\/p>\n\n\n\n

The bio-better strategy is the biologic equivalent of a hard switch, but it is generally more defensible because the clinical differentiation is more substantial. A biologic that requires monthly instead of biweekly injections and demonstrates lower anti-drug antibody rates has a clinical story that IR-to-ER conversions in small molecules rarely can match.<\/p>\n\n\n\n

From an IP valuation standpoint, a brand that successfully converts its prescriber base to a bio-better before biosimilars enter for the original biologic preserves a large portion of the franchise’s revenue with a longer and more defensible exclusivity runway. The risk is that the bio-better development program fails to meet its efficacy endpoints, leaving the brand exposed to biosimilar competition for the original with no successor product.<\/p>\n\n\n\n

Key Takeaways: Biologics<\/strong><\/p>\n\n\n\n

The BPCIA’s 12-year reference product exclusivity creates longer natural protection for biologics than Hatch-Waxman provides for small molecules, reducing the pressure for IP stacking that drives small-molecule product hops. PEGylation and half-life extension are the most IP-efficient biologic lifecycle tools because they generate new molecule status and new reference product exclusivity. Biosimilar interchangeability remains a significant commercial barrier even after the interchangeability designation is obtained, limiting the substitution dynamic that makes small-molecule product hops so financially consequential.<\/p>\n\n\n\n

Investment Strategy: Biologics<\/strong><\/p>\n\n\n\n

For investors, the most important variable in a biologic franchise’s long-term revenue model is whether the brand successfully converts its patient base to a bio-better before biosimilars achieve meaningful formulary placement in the original molecule’s market. A franchise where 70% or more of patients are on the bio-better formulation by the time biosimilars reach meaningful penetration of the original is structurally insulated from the worst of the biosimilar price erosion. Model this conversion rate explicitly.<\/p>\n\n\n\n

\n\n\n\n

The Economic Model: Understanding the Patent Cliff<\/strong><\/h2>\n\n\n\n

Revenue Collapse Dynamics at Generic Entry<\/strong><\/h3>\n\n\n\n

The revenue trajectory of a branded drug post-generic entry follows a predictable pattern that justifies the term ‘patent cliff’ more accurately than almost any other metaphor in finance. The IMS Health (now IQVIA) data on brand revenue erosion is consistent across therapeutic areas: branded unit share typically falls below 20% within six months of a first generic’s entry when there are multiple generic entrants, and below 10% within twelve months.<\/p>\n\n\n\n

The price differential drives this substitution. Generic entrants typically price at 70-85% below the brand’s average wholesale price on day one, competing with each other on price rather than against the brand on clinical attributes. Pharmacy benefit managers (PBMs) place generic equivalents on Tier 1 formulary (lowest co-pay), the brand on Tier 3 or 4 (highest co-pay or prior authorization required), or exclude the brand entirely. The economics of the pharmacy benefit are structured to drive substitution; the pharmacist captures a dispensing fee regardless of which product is dispensed.<\/p>\n\n\n\n

The aggregate impact on a blockbuster with $5 billion in annual U.S. revenue is a loss of roughly $4.25 billion in annual revenue within the first full year post-generic entry. This is not modeled as a risk event; it is a near-certainty. The uncertainty is the exact timing of first generic entry, driven by patent litigation outcomes.<\/p>\n\n\n\n

The Contribution Margin Differential<\/strong><\/h3>\n\n\n\n

What makes the patent cliff economically existential for many brand franchises is not just the revenue loss but the contribution margin differential between the brand and its successor. A blockbuster drug generating $5 billion in revenue at 80-85% gross margins contributes roughly $4 billion annually to cover R&D costs and fund the pipeline. The successor product, even if successfully launched, takes years to build revenue scale. The gap between what the old franchise was generating and what the new pipeline can produce is the ‘innovation gap’ that drives aggressive lifecycle management.<\/p>\n\n\n\n

This dynamic is particularly acute for companies with concentrated revenue bases. A company deriving 40% of its revenue from a single branded product approaching LOE has a structural problem that no amount of lifecycle management can fully solve; it can only be deferred.<\/p>\n\n\n\n

The Investor Math on a Successful Product Hop<\/strong><\/h3>\n\n\n\n

A product hop that successfully transfers 80% of a franchise’s revenue to a new, patent-protected formulation changes the DCF model materially. Instead of modeling a revenue cliff in year three, the analyst now projects a gradual erosion curve beginning at the new formulation’s first patent expiry date, which may be 8-12 years later.<\/p>\n\n\n\n

The discount applied to this revenue stream should account for the Paragraph IV litigation probability on the new formulation’s lead patent, the three-year new clinical investigation exclusivity period, the antitrust litigation risk if the switch involves a hard switch, and the physician and payer acceptance rate for the new formulation.<\/p>\n\n\n\n

A hop that has already achieved 75% penetration into the franchise’s prescription base before the first generic enters the old product’s market is substantially more valuable than one in early stages. That penetration rate should be tracked quarterly from the new product’s launch.<\/p>\n\n\n\n

\n\n\n\n

Competitive Intelligence: How to Detect a Product Hop 24 Months Early<\/strong><\/h2>\n\n\n\n

The Signal Pattern<\/strong><\/h3>\n\n\n\n

Brand companies do not announce product hops. They announce new clinical trials, new patent filings, new FDA submissions, and changes to their investor guidance on franchise durability. These signals, assembled correctly, reconstruct the hop strategy months or years before it is visible in prescribing data.<\/p>\n\n\n\n

The earliest signal is usually a Phase II or III trial registration on ClinicalTrials.gov for a new formulation of a product whose primary API patent expires within three to five years. The trial design is itself informative: a trial powered to demonstrate superiority on an adherence or patient preference endpoint is almost certainly lifecycle management. A trial powered to show superior efficacy is a genuine clinical program.<\/p>\n\n\n\n

The second signal is a new patent filing at the USPTO. Brand companies typically file formulation patents several years before the new product’s NDA, meaning a patent filing on an extended-release or fixed-dose combination formulation can appear in public records three to four years before the product launches commercially. These filings are public immediately upon grant (or 18 months after filing if published before grant).<\/p>\n\n\n\n

The third signal is FDA activity: an NDA submission under Section 505(b)(2) for a modified version of an existing product, or a Supplemental NDA (sNDA) adding new exclusivity-generating data (pediatric studies, new indication) to an existing approved product.<\/p>\n\n\n\n

The fourth signal is investor communications. Brand company executives routinely refer to LOE management, franchise durability, and lifecycle programs in earnings calls. Parsing the language of these calls against the patent and regulatory data identifies where management is directing capital.<\/p>\n\n\n\n

Mapping the Orange Book<\/strong><\/h3>\n\n\n\n

The FDA’s Orange Book is the primary public data source for mapping a franchise’s IP position. It lists all patents the brand company has certified as relevant to the approved product, all exclusivity periods, and the ANDA filing status of any generic challengers.<\/p>\n\n\n\n

For a product hop analysis, the Orange Book comparison between the old product and the new product is critical. When the new formulation receives NDA approval, the brand will list its formulation patents against the new product’s Orange Book entry. The absence of previously listed patents from the new product’s entry, or the appearance of new, longer-dated patents, defines the effective IP extension the hop achieves.<\/p>\n\n\n\n

The gap between the last expiring patent on the old formulation and the last expiring patent on the new formulation is the structural value created by the hop. For Namenda, this gap was approximately a decade. For franchise valuations, this gap is the central variable in the lifecycle management NPV calculation.<\/p>\n\n\n\n

Using Patent Intelligence Platforms<\/strong><\/h3>\n\n\n\n

Monitoring the USPTO, the Orange Book, ClinicalTrials.gov, FDA drug databases, and federal court dockets simultaneously is operationally impractical without specialized infrastructure. Patent intelligence platforms that aggregate and cross-reference these sources reduce the signal detection timeline and alert teams to patent filings and regulatory submissions in near-real-time.<\/p>\n\n\n\n

The practical workflow for a generic company monitoring a target brand: set an alert on the brand’s NDA number for any Orange Book changes, set a patent alert on the brand’s assignee name for new formulation-class filings, track the ClinicalTrials.gov registration for the target molecule’s active ingredient, and monitor PACER for any new patent litigation involving the brand’s related products. This four-source monitoring covers the primary early-warning channels for a product hop.<\/p>\n\n\n\n

Key Takeaways: Competitive Intelligence<\/strong><\/p>\n\n\n\n

A Phase III trial registered on ClinicalTrials.gov with a patient preference or adherence primary endpoint is the earliest reliable signal of a planned product hop. The gap between the old product’s last expiring Orange Book patent and the new product’s first listed patent expiry date quantifies the IP value of the hop. Real-time Orange Book monitoring is a required operational function for any generic company with ANDAs pending against major brand franchises.<\/p>\n\n\n\n

Investment Strategy: Monitoring for LOE Events<\/strong><\/p>\n\n\n\n

Portfolio managers tracking pharmaceutical positions should maintain a LOE calendar that includes not just the API patent expiry dates but all listed exclusivity expiry dates for both the primary and any successor formulations. A brand that has already completed a product hop and achieved high penetration into the new formulation represents a structurally different LOE risk than one that has not initiated a transition. The former is priced as a franchise with a long protected runway; the latter carries both patent cliff risk and transition execution risk.<\/p>\n\n\n\n

\n\n\n\n

The Antitrust Framework: Section 2 and Product Hopping<\/strong><\/h2>\n\n\n\n

The Sherman Act Standard<\/strong><\/h3>\n\n\n\n

Product hopping cases are litigated primarily under Section 2 of the Sherman Antitrust Act, which prohibits willful maintenance of monopoly power through exclusionary conduct. The brand pharmaceutical company has a lawful monopoly during its patent period. The question is whether the specific acts accompanying the product hop cross from lawful monopoly exercise into illegal exclusionary conduct.<\/p>\n\n\n\n

The Supreme Court’s foundational standard in Aspen Skiing Co. v. Aspen Highlands Skiing Corp. (1985) established that a monopolist’s conduct is exclusionary when it makes no economic sense except as a means to harm competition. The FTC has applied this framework to pharmaceutical product hopping in arguing that a hard switch, viewed in isolation from its competitive effect, is economically irrational: the brand already has a patent on the new formulation protecting it from competition. The only reason to also withdraw the old formulation is to block the generic from entering a market at all.<\/p>\n\n\n\n

The Preponderance of Evidence on Intent<\/strong><\/h3>\n\n\n\n

Courts in product hopping cases have not adopted a rigid rule. They apply a burden-shifting framework: the plaintiff must show that the conduct has anti-competitive effects, then the defendant must demonstrate pro-competitive justifications, then the plaintiff can rebut by showing the anti-competitive harm outweighs those justifications.<\/p>\n\n\n\n

The brand’s strongest pro-competitive justification is the patient benefit of the new formulation. Where that benefit is clinically demonstrated, meaningful, and not easily achievable through the generic of the old product (e.g., a once-monthly injection replacing a twice-weekly one), courts have been reluctant to restrict the brand’s conduct. Where the benefit is marginal or primarily a matter of repackaging, courts have been more receptive to plaintiffs’ arguments.<\/p>\n\n\n\n

The Suboxone litigation’s use of internal documents to undercut the brand’s stated rationale illustrates that the intent evidence available to plaintiffs can effectively rebut a pro-competitive justification even when the justification has surface plausibility. A safety rationale that company communications show was secondary to competitive defense is a weak defense.<\/p>\n\n\n\n

State AG Enforcement and Multi-Party Litigation<\/strong><\/h3>\n\n\n\n

The Namenda case was initiated by the New York Attorney General’s office, not the FTC, demonstrating that state-level enforcement is a viable and potent channel for product hopping antitrust challenges. The NYAG’s ability to obtain a preliminary injunction, which is a high evidentiary bar requiring a showing of likely success on the merits and irreparable harm, was itself a significant precedent.<\/p>\n\n\n\n

Multiple state AGs now coordinate pharmaceutical antitrust enforcement through the Multistate Antitrust Task Force. A brand company planning a hard switch should assess not just federal antitrust risk but the likelihood of coordinated state AG action, particularly in states with large Medicaid programs that bear a disproportionate share of the cost of delayed generic entry.<\/p>\n\n\n\n

Direct purchaser class actions (wholesalers and retail pharmacies) and end-payer class actions (insurers and PBMs) are the other litigation channels. These cases have longer resolution timelines than government enforcement actions but can result in substantial damages awards based on the aggregate value of delayed generic savings across all purchasers.<\/p>\n\n\n\n

\n\n\n\n

Responding to a Product Hop: Strategies for Generic Companies<\/strong><\/h2>\n\n\n\n

The ANDA Portfolio Defense<\/strong><\/h3>\n\n\n\n

Generic companies facing a product hop have several tactical responses. The first and most important is pre-hop preparation: anticipating the new formulation based on competitive intelligence and beginning ANDA development for the new product in parallel with the existing ANDA for the original. A generic company that files a Paragraph IV ANDA against the new formulation’s lead patent the same week the new product launches has compressed the competitive gap to the minimum achievable.<\/p>\n\n\n\n

The 180-day first-filer exclusivity provision creates an incentive to be the first generic ANDA filer against any listed patent on the new formulation. A generic that is the first Paragraph IV filer against a key formulation patent on the hopped product gets six months of exclusive generic marketing upon launch, which at typical biologic price discounts can represent hundreds of millions of dollars in incremental revenue.<\/p>\n\n\n\n

At-Risk Launch Calculations<\/strong><\/h3>\n\n\n\n

An at-risk launch, where a generic company launches commercially before all patent litigation is fully resolved, requires a probability-weighted assessment of the litigation outcome. If the lead patent on the new formulation is narrowly written, covers only a specific excipient combination that the generic can design around, or is asserted on a formulation patent rather than the API, an at-risk launch may be economically justified.<\/p>\n\n\n\n

The risk calculation must include the damages exposure if the brand prevails in the underlying patent litigation, typically measured as lost profits or a reasonable royalty. For a major brand product, these damages can be substantial. At-risk launches are therefore more common when the generic company has strong invalidity arguments (prior art, obviousness) rather than non-infringement arguments, because invalidity if proven eliminates the damages exposure entirely.<\/p>\n\n\n\n

Antitrust Claims as a Strategic Tool<\/strong><\/h3>\n\n\n\n

Generic companies that have been harmed by a product hop have standing to bring antitrust claims for damages equal to three times their actual losses (treble damages under Section 4 of the Clayton Act). The calculation of ‘actual losses’ in this context is the generic company’s lost profits from the market that was destroyed by the hard switch.<\/p>\n\n\n\n

These claims are increasingly filed proactively by generic companies alongside their patent litigation, rather than as a separate subsequent action. The consolidation of patent and antitrust claims in a single litigation creates more discovery leverage and can accelerate settlement.<\/p>\n\n\n\n

\n\n\n\n

Payer and Policy Responses<\/strong><\/h2>\n\n\n\n

Formulary Architecture as a Defense<\/strong><\/h3>\n\n\n\n

PBMs and insurers have developed formulary management tools specifically designed to preserve generic savings even when a brand attempts a product hop. Step therapy requirements can mandate that patients use the generic of the old formulation before the brand will cover the new hopped product. Prior authorization requirements create physician engagement that makes the transition sticky to generics rather than to the brand.<\/p>\n\n\n\n

Non-medical switching policies, controversial in their own right, permit payers to move patients from a newly covered brand product to a therapeutically equivalent generic when one becomes available, even if the specific formulation is not an exact equivalent. Some PBMs have adopted policies that treat a generic IR formulation as therapeutically equivalent to a branded XR formulation for step therapy purposes, directly countering the hop strategy at the formulary level.<\/p>\n\n\n\n

Legislative Proposals<\/strong><\/h3>\n\n\n\n

Several legislative proposals have been introduced in Congress to address product hopping specifically, though none have been enacted as of the date of this writing. The CREATES Act (Creating and Restoring Equal Access to Equivalent Samples), enacted in 2019, addressed a related but distinct problem: brand companies withholding reference drug samples from generic and biosimilar developers, which is a different form of market foreclosure. The CREATES Act created a private right of action for generic developers unable to obtain samples.<\/p>\n\n\n\n

More targeted proposals have included amendments to the Hatch-Waxman Act that would presume a product withdrawal within two years of a first Paragraph IV ANDA filing to be anti-competitive, and bills that would extend the therapeutic equivalence standard for automatic substitution to include a regulatory finding of therapeutic equivalence rather than requiring identical formulation. Neither has advanced to a floor vote.<\/p>\n\n\n\n

The FTC’s Prescription Drug Pricing Study, published in 2022, identified product hopping as a significant contributor to brand-to-generic substitution failure and called for legislative action. The report’s policy recommendations remain the most detailed official articulation of potential reforms.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways: Full Article<\/strong><\/h2>\n\n\n\n

Drug product hopping is a lifecycle management strategy in which a brand manufacturer transitions the market from a patent-expiring formulation to a reformulated, patent-protected version, timed to preempt automatic generic substitution under state pharmacy law.<\/p>\n\n\n\n

The four primary execution tactics are IR-to-ER conversion, dosage form switching, fixed-dose combination development, and enantiomer or molecular reformulation. Each creates a new Orange Book listing that is not substitutable with generics of the original product.<\/p>\n\n\n\n

The legal distinction between a soft switch and a hard switch is the controlling variable in antitrust risk. A soft switch (marketing-led transition, old product remains available) is generally lawful. A hard switch (withdrawal of the old product before generic entry) can constitute illegal monopoly maintenance under Section 2 of the Sherman Act, per the Second Circuit’s Namenda decision.<\/p>\n\n\n\n

The IP value of a hopped product is captured in the gap between the old formulation’s patent expiry and the new formulation’s last listed exclusivity or patent date. Three-year new clinical investigation exclusivity and stacked formulation patents on the new product drive this gap. For major franchises, the gap has ranged from four to twelve years.<\/p>\n\n\n\n

Hatch-Waxman exclusivity stacking (three-year new clinical investigation exclusivity plus pediatric exclusivity plus formulation patents plus 30-month stays) is the IP infrastructure that makes a product hop durable. Generic companies must map all exclusivity periods, not just patent expiry dates, to model their entry timeline accurately.<\/p>\n\n\n\n

In biologics, PEGylation and half-life extension are the structural analogs of small-molecule product hopping. The BPCIA’s 12-year reference product exclusivity provides longer baseline protection, but bio-better strategies can extend a franchise’s protected period substantially.<\/p>\n\n\n\n

A product hop is detectable 24 to 36 months before commercial launch by monitoring Phase III trial registrations on ClinicalTrials.gov, new formulation patent filings at the USPTO, Orange Book changes, and management commentary in SEC filings and earnings calls.<\/p>\n\n\n\n

The Reckitt Benckiser $1.4 billion Suboxone settlement is the binding precedent on the financial consequences of an intent-visible, coercively executed hard switch. Internal documents documenting competitive rationale rather than patient benefit rationale are the most damaging evidence in product hop antitrust litigation.<\/p>\n\n\n\n

Payer tools (step therapy, non-medical switching, prior authorization) can partially neutralize a soft-switch product hop at the formulary level but are less effective against a hard switch, because the old product is gone and there is no generic to substitute.<\/p>\n\n\n\n

\n\n\n\n

References<\/strong><\/h2>\n\n\n\n

DiMasi, J. A., Grabowski, H. G., and Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.<\/p>\n\n\n\n

New York ex rel. Schneiderman v. Actavis plc, 787 F.3d 638 (2d Cir. 2015).<\/p>\n\n\n\n

Mylan Pharmaceuticals, Inc. v. Warner Chilcott Public Limited Company, No. 12-3824 (E.D. Pa. 2015); see also analysis in Third Circuit doctrine on sequential product switches.<\/p>\n\n\n\n

Federal Trade Commission, Press Release: Reckitt Benckiser Group to Pay $1.4 Billion to Resolve U.S. Allegations Related to the Marketing of Suboxone (July 9, 2019).<\/p>\n\n\n\n

Berndt, E. R. and Aitken, M. (2011). Brand loyalty, generic entry and price competition in pharmaceuticals in the late 1990s. In The Changing Economics of The Pharmaceutical Industry, Edward Elgar Publishing.<\/p>\n\n\n\n

Federal Trade Commission. Generic Drug Entry Prior to Patent Expiration: An FTC Study (2002); FTC Report on Pharmacy Benefit Managers: Efficiency, Transparency, and Competition (2005).<\/p>\n\n\n\n

U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), current edition.<\/p>\n\n\n\n

Sherman Antitrust Act, 15 U.S.C. Sections 1-7; Clayton Act, 15 U.S.C. Section 15.<\/p>\n\n\n\n

Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. 98-417 (Hatch-Waxman Act).<\/p>\n\n\n\n

Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. Section 262 (BPCIA).<\/p>\n\n\n\n

Creating and Restoring Equal Access to Equivalent Samples Act, Pub. L. 116-94 (CREATES Act, 2019).<\/p>\n\n\n\n

Federal Trade Commission. Prescription Drug Pricing Study: An FTC Report (2022).<\/p>\n","protected":false},"excerpt":{"rendered":"

A brand-name drug loses 90% of its market share within 12 months of generic entry. That single data point explains […]<\/p>\n","protected":false},"author":1,"featured_media":35525,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-32831","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=32831"}],"version-history":[{"count":3,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32831\/revisions"}],"predecessor-version":[{"id":38755,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32831\/revisions\/38755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/35525"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=32831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=32831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=32831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}